Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 10.9% Following Insider Selling

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 10.9% on Friday following insider selling activity. The stock traded as low as $3.38 and last traded at $3.3850. 9,626,800 shares were traded during mid-day trading, a decline of 44% from the average session volume of 17,224,771 shares. The stock had previously closed at $3.80.

Specifically, Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total value of $110,400.00. Following the completion of the transaction, the director owned 6,169,863 shares in the company, valued at approximately $22,705,095.84. This represents a 0.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Morgan Stanley increased their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. JPMorgan Chase & Co. dropped their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Finally, Wall Street Zen cut Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Stock Down 11.2%

The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -2.81 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. The business’s 50-day moving average is $3.30 and its 200-day moving average is $3.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same period last year, the firm posted ($0.50) EPS. The business’s revenue was down 56.8% on a year-over-year basis. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.02 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in Recursion Pharmaceuticals by 18.2% during the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares in the last quarter. Janus Henderson Group PLC increased its position in Recursion Pharmaceuticals by 59.4% in the 1st quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock valued at $675,000 after acquiring an additional 82,100 shares in the last quarter. California State Teachers Retirement System increased its position in Recursion Pharmaceuticals by 64.0% in the 1st quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after acquiring an additional 224,332 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Recursion Pharmaceuticals by 7.3% in the first quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock worth $675,000 after acquiring an additional 15,049 shares during the last quarter. Finally, Themes Management Co LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $236,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.